Treatment with Open Eyes: Markers-Guided Chronotheranostics

Chronopharmaceutics: Science and Technology for Biological Rhythm-Guided Therapy and Prevention of Diseases

Volumn , Issue , 2009, Pages 257-323

  Cornélissen, Germaine ^a   Halberg, Franz ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Chronopharmacology and chronotherapy; Markers guided chronotheranostics; Transplantation applications

Indexed keywords

EID: 84859495355     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470498392.ch11     Document Type: Chapter

References (141)

1. Halberg F, Cornélissen G, Halberg J, Fink H, Chen CH, Otsuka K, Watanabe Y, Kumagai Y, Syutkina EV, Kawasaki T, Uezono K, Zhao ZY, Schwartzkopff O. Circadian hyper-amplitude-tension, CHAT: a disease risk syndrome of anti-aging medicine. J Anti-Aging Med. 1998; 1: 239-259.
2. Cornélissen G, Halberg F, Bakken EE, Singh RB, Otsuka K, Tomlinson B, Delcourt A, Toussaint G, Bathina S, Schwartzkopff O, Wang ZR, Tarquini R, Perfetto F, Pantaleoni GC, Jozsa R, Delmore PA, Nolley E. 100 or 30 years after Janeway or Bartter, Healthwatch helps avoid ''flying blind.'' Biomed Pharmacother. 2004; 58(suppl 1): S69-S86.
3. Halberg F, Cornélissen G, Wang ZR, Wan C, Ulmer W, Katinas G, Singh Ranjana, Singh RK, Singh Rajesh, Gupta BD, Singh RB, Kumar A, Kanabrocki E, Sothern RB, Rao G, Bhatt MLBD, Srivastava M, Rai G, Singh S, Pati AK, Nath P, Halberg F, Halberg J, Schwartzkopff O, Bakken E, Shastri VK. Chronomics: circadian and circaseptan timing of radiotherapy, drugs, calories, perhaps nutriceuticals and beyond. J Exp Ther Oncol. 2003; 3: 223-260.
4. Halberg F, Cornélissen G, International Womb-to-Tomb Chronome Initiative Group. Resolution from a meeting of the International Society for Research on Civilization Diseases and the Environment (New SIRMCE Confederation), Brussels, Belgium, March 17-18, 1995. Fairy Tale or reality? Medtronic Chronobiology Seminar #8, April 1995, 12 pp. text, 18 figures. Available at http://www.msi.umn.edu/Bhalberg/.
5. Halberg F. When to treat. Hæmatologica (Pavia). 1975; 60: 1-30.
6. Carandente A, Halberg F. Drug industry and chronobiology: achievements and prospects. Ann NY Acad Sci. 1991; 618: 484-489.
7. Halberg F. Protection by timing treatment according to bodily rhythms: an analogy to protection by scrubbing before surgery. Chronobiologia. 1974; 1(suppl 1): 27-68.
8. Ertel RJ, Halberg F, Ungar F. Circadian system phase-dependent toxicity and other effects of methopyrapone (SU-4885) in mice. J Pharmacol Exp Ther. 1964; 146: 395-399.
9. Bingham C, Cornélissen G, Halberg F. Power of Phase 0 chronobiologic trials at different signal-to-noise ratios and sample sizes. Chronobiologia. 1993; 20: 179-190.
10. Cornélissen G, Bingham C, Wilson D, Halberg F. Illustrating power of costeffective ''Phase 0'' chronobiologic trials in endocrinology, psychiatry and oncology. In: Cornélissen G, Halberg E, Bakken E, Delmore P, Halberg F, eds. Toward Phase Zero Preclinical and Clinical Trials: Chronobiologic Designs and Illustrative Applications. University of Minnesota Medtronic Chronobiology Seminar Series #6, September 1992, pp 138-181.
11. Halberg F, Bingham C, Cornélissen G. Clinical trials: the larger the better? Chronobiologia. 1993; 20: 193-212.
12. Zaslavskaya RM. Chronodiagnosis and Chronotherapy of Cardiovascular Diseases, 2nd ed. Translation into English from Russian. Moscow: Medicina; 1993.
13. Halberg F, Halberg J, Halberg E, Halberg F. Chronobiology, radiobiology and steps toward the timing of cancer radiotherapy. In: Kaiser H, ed. Cancer Growth and Progression, vol 9, chap 19. Dordrecht: Kluwer Academic Publishers; 1989: 227-253.
14. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Brit J Cancer. 1976; 34: 585-612.
15. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977; 35: 1-39.
16. Fedorov VV, Khabarov V. Duality of optimal designs for model discrimination and parameter estimation. Biometrika. 1986; 73: 183-190.
17. Kitsos CP, Titterington DM, Torsney B. An optimal design problem in rhythmometry. Biometrics. 1988; 44: 657-671.
18. Bingham C, Arbogast B, Cornélissen Guillaume G, Lee JK, Halberg F. Inferential statistical methods for estimating and comparing cosinor parameters. Chronobiologia. 1982; 9: 397-439.
19. Hawkins DM. Self-starting cusum charts for location and scale. Statistician. 1987; 36: 299-315.
20. Cornélissen G, Halberg F, Hawkins D, Otsuka K, Henke W. Individual assessment of antihypertensive response by self-starting cumulative sums. J Med Eng Technol. 1997; 21: 111-120.
21. Johnson EA, Haus E, Halberg F, Wadsworth GL. Graphic monitoring of seizure incidence changes in epileptic patients. Minn Med. 1959; 42: 1250-1257.
22. Halberg F. Temporal coordination of physiologic function. Cold Spring Harb Symp Quant Biol. 1960; 25: 289-310.
23. Halberg F. Biological as well as physical parameters relate to radiology. Guest Lecture, Proceedings of the 30th Annual Congress Radiology, January 1977, Post-Graduate Institute of Medical Education and Research, Chandigarh, India.
24. Halberg F, Prem K, Halberg F, Norman C, Cornélissen G. Cancer chronomics I: origins of timed cancer treatment: early marker rhythm-guided individualized chronochemotherapy. J Exp Ther Oncol. 2006; 6: 55-61.
25. Haus E, Fernandes G, Kühl JFW, Yunis EJ, Lee JK, Halberg F. Murine circadian susceptibility rhythm to cyclophosphamide. Chronobiologia. 1974; 1: 270-277.
26. Halberg F, Halberg E, Haus E, Walker R, Fujii S, Berg H, Takagi M, Cornélissen G. Markers for the diagnosis and prevention of malignancy. Bioquimia. 1994; 19: 41-42.
27. Halberg F, Cornélissen G, Bingham C, Fujii S, Halberg E. From experimental units to unique experiments: chronobiologic pilots complement large trials. In vivo. 1992; 6: 403-428.
28. Cornélissen G, Halberg F. Introduction to Chronobiology. Medtronic Chronobiology Seminar #7, April 1994. (Library of Congress Catalog Card #94-060580). Available at http://www.msi.umn.edu/Bhalberg.
29. Cornélissen G, Halberg F, Walker R, Zaslavskaya RM, Fine RL, Haus E. Chronobiologic aspects of urinary gonadotropin peptide (UGP). In Vivo. 1995; 9: 359-362.
30. Xu FJ, Yu YH, Bast RC Jr, Cornélissen G, Fujii S, Takagi M, O'Brien T, Halberg F. Toward salivary-urinary chronosensitivity testing: chronomes of OVX1, MCSF and CA130. In Vivo. 1995; 9: 407-412.
31. Halberg E, Long HJ III, Cornélissen G, Blank MA, Elg S, Touitou Y, Bakken E, Delmore P, Haus E, Sackett-Lundeen L, Prem K, Halberg F. Toward a chronotherapy of ovarian cancer with taxol: Part II: Test pilot study on CA125. Chronobiologia. 1992; 19: 17-42.
32. Cornélissen G, Halberg F, Halberg E, Bingham C, Haus E, Bast RC Jr, Fujii S, Long HJ III, Halberg F, Tamura K. Toward a chronotherapy of ovarian cancer. Part III: Salivary CA125 for chronochemotherapy by efficacy. Chronobiologia. 1992; 19: 131-149.
33. Halberg E, Cornélissen G, Haus E, Fine RL, Walker R, Von Hoff D, Halberg F, Halberg J, Halberg F. Amplification [on comments by Berry DA. Power of chronobiologic pilots: a statistician's opinion. Chronobiologia. 1993; 20: 213-214]. Chronobiologia. 1993; 20: 218-.
34. Klevecz RR, Shymko RM, Blumenfeld D, Braly PS. Circadian gating of S-phase in human ovarian cancer. Caner Res. 1987; 47: 6267-6271.
35. Elg S, Halberg E, Ramakrishnan R, Cornélissen G, Haus E, Nicolau G, Carson L, Twiggs L, Long HJ III, Halberg F. Marker rhythmometry with macrophage colony stimulating factor (M-CSF). Chronobiologia. 1991; 18: 141-152.
36. Carenza L, Villani C, Rulli G, Labi FL, Prosperi Port R. Ovarian cancer: relationship between in vitro chromosensitivity and clinical response. Gynecol Oncol. 1990; 36: 13-18.
37. Fine RL, Cornélissen G, Haus E, Bast RC Jr, Walker R, Berg H, Jatoi A, Dahl J, Sturner ML, Nelson R, Cardarelli I, Mikhail L, Hunter D, Halberg J, Halberg F, Von Hoff DD, Halberg F, Halberg E. Erna-test: chemosensitivity assays and marker rhythmometry target cancer treatment in time and kind. 16th World Congress of Anatomic and Clinical Pathology, Acapulco, Mexico, October 5-9, 1993.
38. Levi F, Zidani R, Brienza S, Dogliotti L, Perpoint B, Rotarski M, Letourneau Y, Llory JF, Chollet P, Le Rol A, Focan C. A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. Cancer. 1999; 85: 2532-2540.
39. Halberg F, Gupta BD, Haus E, Halberg E, Deka AC, Nelson W, Sothern RB, Cornélissen G, Lee JK, Lakatua DJ, Scheving LE, Burns ER. Steps toward a cancer chronopolytherapy. In: Proceedings of the XIV International Congress of Therapeutics. Montpellier, France: L'Expansion Scientifique Franc- aise; 1977: 151-196.
40. Halberg F, Haus E, Cardoso SS, Scheving LE, Kühl JFW, Shiotsuka R, Rosene G, Pauly JE, Runge W, Spalding JF, Lee JK, Good RA. Toward a chronotherapy of neoplasia: tolerance of treatment depends upon host rhythms. Experientia (Basel). 1973; 29: 909-934.
41. Hrushesky WJM. The clinical application of chronobiology to oncology. Am J Anat. 1983; 168: 519-542.
42. Hrushesky WJM. Automatic chronotherapy: an integral part of the future of medicine. In: Hekkens WTJM, Kerkhof GA, Rietveld WJ, eds. Trends in Chronobiology. Oxford, UK: Pergamon Press; 1988: 281-293.
43. Cornélissen G, Halberg F. The chronobiologic pilot study with special reference to cancer research: Is chronobiology or, rather, its neglect wasteful? In: Kaiser H, ed. Cancer Growth and Progression, vol 9. chap 9. Dordrecht: Kluwer Academic Publishers; 1989: 103-133.
44. Kennedy BJ. A lady and chronobiology. Chronobiologia. 1993; 20: 139-144.
45. Blank MA, Gushchin VA, Halberg F, Portela A, Cornélissen G. X-irradiation chronosensitivity and circadian rhythmic proliferation in healthy and sarcomacarrying rats' bone marrow. In Vivo. 1995; 9: 395-400.
46. Halberg F, Cornélissen G, Schwartzkopff O, Katinas GS, Chibisov SM, Khalitskaya EV, Mitsutake G, Otsuka K, Scheving LA, Bakken EE. Chronometaanalysis: magnetic storm associated with a reduction in circadian amplitude of rhythm in corneal cell division. In: International Conference on the Frontiers of Biomedical Science: Chronobiology, Chengdu, China, September 24-26, 2006, pp 40-42.
47. Blank MA, Blank OA, Duke VA. The hemodepressive effect of irradiation in humans. Dokl Biol Sci. 2003; 393: 424-426.
48. Blank MA, Blank OA, Gershanovich ML. Influence of geomagnetic activity on mustophoran hematotoxicity. Dokl Biol Sci. 2005; 404: 835-838.
49. Takahashi R, Halberg F, Walker C, eds. Toward Chronopharmacology. New York: Pergamon Press; 1982 .
50. Di Santo A, Chodos D, Halberg F. Chronobioavailability of three erythromycin test preparations assessed by each of four indices: time to peak, peak, nadir and area. Chronobiologia. 1975; 2(suppl 1): 17.
51. Morris PJ. Cyclosporin A overview. Transplantation. 1981; 32: 349-354.
52. Ferguson RM, Rynasiewicz JJ, Sutherland DER, Simmons RS, Najarian JS. Cyclosporin A in renal transplantation. A prospective randomized trial. Surgery. 1982; 92: 175-182.
53. Cavallini M, Halberg F, Sutherland DER, Cornélissen G, Heil J, Najarian JS. Optimization by timing of oral cyclosporine to prevent acute kidney allograft rejection in dogs. Transplantation. 1986; 41: 654-657.
54. Magnus G, Cavallini M, Halberg F, Cornélissen G, Sutherland D, Hrushesky W, Najarian JS. Circadian toxicology of cyclosporine. Toxicol Appl Pharmacol. 1985; 77: 181-185.
55. Cavallini M, Magnus G, Halberg F, Liu T, Field MY, Sibley R, Najarian JS, Sutherland DER. Benefit from circadian timing of cyclosporine revealed by delay of rejection of murine heart allograft. Transplant Proc. 1983; 15(4, suppl 1): 2960-2966.
56. Cavallini M, Halberg F, Cornélissen G, Enrichens F, Margarit C. Organ transplantation and broader chronotherapy with implantable pump and computer programs for marker rhythm assessment. J Control Release. 1986; 3: 3-13.
57. DeVecchi A, Carandente F, Fryd DS, Halberg F, Sutherland DE, Howard RJ, Simmons RL, Najarian JS. Circaseptan (about 7-day) rhythm in human kidney allograft rejection in different geographic locations. In: Reinberg A, Halberg F, eds. Chronopharmacology, Proceedings of the Satellite Symposium of the 7th International Congress on Pharmacology, Paris 1978. New York: Pergamon Press; 1979: 193-202.
58. Liu T, Cavallini M, Halberg F, Cornélissen G, Field J, Sutherland DER. More on the need for circadian, circaseptan and circannual optimization of cyclosporine therapy. Experientia. 1986; 42: 20-22.
59. Cornélissen G, Gubin D, Halberg F, Milano G, Halberg F. Chronomedical aspects of oncology and geriatrics (review). In Vivo. 1999; 13: 77-82.
60. Halberg E, Halberg F. Chronobiologic study design in everyday life, clinic and laboratory. Chronobiologia. 1980; 7: 95-120.
61. Rottembourg J, Mattei MF, Cabrol A, Leger P, Aupetit B, Beaufils H, Gluckman JC, Pavie A, Gandjbakhch I, Cabrol C. Renal function and blood pressure in heart transplant recipients treated with cyclosporine. J Heart Transplant. 1985; 4: 404-408.
62. McDonald K, Sanchez de la Peña S, Cavallini M, Olivari MT, Cohn JN, Halberg F. Chronobiologic blood pressure and heart rate assessment of patients with heart transplants. Prog Clin Biol Res. 1990; 341B: 471-480.
63. Lenfant C. Reflections on hypertension control rates: a message from the director of the National Heart, Lung, and Blood Institute. Arch Intern Med. 2002; 162: 131-132.
64. Veerman DP, de Blok K, Elemarre BJ, van Montfrans GA. Office, nurse, basal and ambulatory blood pressure as predictors of hypertensive target organ damage in male and female patients. J Hum Hypertens. 1996; 10: 9-15.
65. Cornélissen G, Halberg F. Impeachment of casual blood pressure measurements and the fixed limits for their interpretation and chronobiologic recommendations. Ann NY Acad Sci. 1996; 783: 24-46.
66. Cornélissen G, Otsuka K, Halberg F. Blood pressure and heart rate chronome mapping: a complement to the human genome initiative. In: Otsuka K, Cornélissen G, Halberg F, eds. Chronocardiology and Chronomedicine: Humans in Time and Cosmos. Tokyo: Life Science Publishing; 1993: 16-48.
67. Nelson W, Cornélissen G, Hinkley D, Bingham C, Halberg F. Construction of rhythm-specified reference intervals and regions, with emphasis on ''hybrid'' data, illustrated for plasma cortisol. Chronobiologia. 1983; 10: 179-193.
68. Halberg F, Drayer JIM, Cornélissen G, Weber MA. Cardiovascular reference data base for recognizing circadian mesor- and amplitude-hypertension in apparently healthy men. Chronobiologia. 1984; 11: 275-298.
69. Halberg F. Chronobiology. Annu Rev Physiol. 1969; 31: 675-725.
70. Halberg F. Chronobiology: methodological problems. Acta Med Rom. 1980; 18: 399-440.
71. Cornélissen G, Halberg F. Chronomedicine In: Armitage P, Colton T, eds. Encyclopedia of Biostatistics, 2nd ed. Chichester, UK: John Wiley & Sons Ltd; 2005: 796-812.
72. Zachariah PK, Sheps SG, Ilstrup DM, Long CR, Bailey KR, Wiltgen CM, Carlson CA. Blood pressure load - a better determinant of hypertension. Mayo Clinic Proc. 1988; 63: 1085-1091.
73. Cornélissen G, Haus E, Halberg F. Chronobiologic blood pressure assessment from womb to tomb. In: Touitou Y, Haus E, eds. Biological Rhythms in Clinical and Laboratory Medicine. Berlin: Springer-Verlag; 1992: 428-452.
74. White WB. Analysis of ambulatory blood pressure data in antihypertensive drug trials. J Hypertens. 1991; 9(suppl 1): S27-S32.
75. National High Blood Pressure Education Program Coordinating Committee Working Group Report on Ambulatory Blood Pressure Monitoring. Arch Intern Med. 1990; 150: 2270-2280.
76. Cornélissen G, Halberg F, Bingham C, Kumagai Y. Toward engineering for blood pressure surveillance. Biomed Instrum Technol. 1997; 31: 489-498.
77. Cornélissen G, Halberg F, Bingham C, Kumagai Y. More on software chronobioengineering for blood pressure surveillance. Biomed Instrum Technol. 1997; 31: 511-513.
78. Cornélissen G, Siegelova J, Halberg F. Blood pressure and heart rate dynamics during pregnancy and early extra-uterine life: methodology for a chrononeonatology. In: Halberg F, Kenner T, Fiser B, eds. Proceedings, Symposium: The Importance of Chronobiology in Diagnosing and Therapy of Internal Diseases. Faculty of Medicine, Masaryk University, Brno, Czech Republic, January 10-13, 2002. Brno: Masaryk University; 2002: 58-96.
79. Kshirsagar AV, Carpenter M, Bang H, Wyatt SB, Colindres RE. Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. Am J Med. 2006; 119: 133-141.
80. Magometschnigg D. Definition und Klassifikation der Hypertonie. J Hyperton. 2004; 8: 12-13. Deutsche Hochdruckliga e.V. (DHL) und Deutsche Hypertoniegesellschaft (DHL/DHG). Leitlinien zur Hypertonie. Available at http://www.paritaet.org/RR-Liga/Hypertonie-Leitlinien05.pdf.
81. Hagen P, ed. Mayo Clinic Guide to Self-Care: Answers for Everyday Health Problems. Rochester, MN: Mayo Clinic; 2003: 180-181.
82. Taylor AL, Lindenfeld J, Ziesche S, Walsh MN, Mitchell JE, Adams K, Tam SW, Ofili E, Sabolinski ML, Worcel M, Cohn JN, A-HeFT Investigators. Outcomes by gender in the African-American Heart Failure Trial. J Am Coll Cardiol. 2006; 48: 2263-2267.
83. Hayes SN, Taler SJ. Hypertension in women: current understanding of gender differences. Mayo Clin Proc. 1998; 73: 157-165.
84. Celis H, Fagard RH, Staessen JA, Thijs L. Systolic Hypertension in Europe Trial Investigators. Risk and benefit of treatment of isolated hypertension in the elderly: evidence from the Systolic Hypertension in Europe Trial. Curr Opin Cardiol. 2001; 16: 342-348.
85. Kleiger RE, Miller JP, Bigger JT, Moss AJ. Multicenter Post-Infarction Research Group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol. 1987; 59: 256-262.
86. Tsuji H, Venditti FJ, Manders ES, Evans JC, Larson MG, Feldman CL, Levy D. Reduced heart rate variability and mortality risk in an elderly cohort: the Framingham Heart Study. Circulation. 1994; 90: 878-883.
87. Otsuka K, Cornélissen G, Halberg F. Predictive value of blood pressure dipping and swinging with regard to vascular disease risk. Clin Drug Investi. 1996; 11: 20-31.
88. Otsuka K, Cornélissen G, Halberg F. Circadian rhythmic fractal scaling of heart rate variability in health and coronary artery disease. Clin Cardiol. 1997; 20: 631-638.
89. Otsuka K, Cornélissen G, Halberg F. Age, gender and fractal scaling in heart rate variability. Clin Sci. 1997; 93: 299-308.
90. Otsuka K, Cornélissen G, Halberg F. Heart rate variability measures and the autonomic nervous function. Diagn Treatment. 1997; 85: 1500-1506.
91. Otsuka K, Cornélissen G, Halberg F, Oehlert G. Excessive circadian amplitude of blood pressure increases risk of ischemic stroke and nephropathy. J Med Eng Technol. 1997; 21: 23-30.
92. Baevsky RM, Petrov VM, Cornélissen G, Halberg F, Orth-Gomér K, Åkerstedt T, Otsuka K, Breus T, Siegelova J, Dusek J, Fiser B. Meta-analyzed heart rate variability, exposure to geomagnetic storms, and the risk of ischemic heart disease. Scr Med. 1997; 70: 199-204.
93. Nakano S, Fukuda M, Hotta F, Ito T, Ishii T, Kitazawa M, Nishizawa M, Kigoshi T, Uchida K. Reversed circadian blood pressure rhythm is associated with occurrence of both fatal and nonfatal vascular events in NIDDM subjects. Diabetes. 1998; 47: 1501-1506.
94. Sanchez de la Pena S, Gonzalez C, Cornélissen G, Halberg F. Blood pressure (BP), heart rate (HR) and non-insulin-dependent diabetes mellitus (NIDDM) chronobiology. Abstract S8-06, 3rd International Congress on Cardiovascular Disease, Taipei, Taiwan, November 26-28, 2004. Int J Cardiol. 2004; 97(suppl 2): S14.
95. Cornélissen G, Chen CH, Halberg F. Predictive value of blood pressure variability: merits of circadian parameters versus dipping patterns. N Engl J Med. 2006; 355: 850.
96. Cornélissen G, Halberg F, Otsuka K, Singh RB, Chen CH. Chronobiology predicts actual and proxy outcomes when dipping fails. Hypertension. 2007; 49: 237-239.
97. Halberg F, Cornélissen G, Halberg J, Schwartzkopff O. Pre-hypertensive and other variabilities also await treatment. Am J Med. 2007; 120: e19-e20.
98. Mancia G, Frattola A, Parati G, Santucciu C, Ulian L. Blood pressure variability and organ damage. J Cardiovasc Pharmacol. 1994; 24(suppl A): S6-S11.
99. Parati G, Di Rienzo M, Ulian L, Santucciu C, Girard A, Elghozi JL, Mancia G. Clinical relevance of blood pressure variability. J Hypertens. 1998; 16: S25-S33.
100. Verdecchia P, Schillaci G, Guerrieri M, Gatteschi C, Benemio G, Boldrini F, Porcellati C. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation. 1990; 81: 528-536.
101. Chen CH, Cornélissen G, Siegelova J, Halberg F. Does overswinging provide an early warning of cardiovascular disease risk when non-dipping may fail? A metaanalysis of 2039 cases. Scr Med. 2001; 74: 75-80.
102. Cornélissen G, Chen CH, Siegelova J, Halberg F. Vascular disease risk syndromes affecting both MESOR-normotensives and MESOR-hypertensives: a metaanalysis of 2039 cases. Scr Med. 2001; 74: 81-86.
103. Cornélissen G, Otsuka K, Chen CH, Kumagai Y, Watanabe Y, Halberg F, Siegelova J, Dusek J. Nonlinear relation of the circadian blood pressure amplitude to cardiovascular disease risk. Scr Med. 2000; 73: 85-94.
104. Parati G, Saul JP, Di Rienzo M, Mancia G. Spectral analysis of blood pressure and heart rate variability in evaluating cardiovascular regulation. Hypertension. 1995; 25: 1276-1286.
105. Halberg F, Cornélissen G, Katinas G, Tvildiani L, Gigolashvili M, Janashia K, Toba T, Revilla M, Regal P, Sothern RB, Wendt HW, Wang ZR, Zeman M, Jozsa R, Singh RB, Mitsutake G, Chibisov SM, Lee J, Holley D, Holte JE, Sonkowsky RP, Schwartzkopff O, Delmore P, Otsuka K, Bakken EE, Czaplicki J, International BIOCOS Group. Chronobiology's progress: Part II, chronomics for an immediately applicable biomedicine. J Appl Biomedi. 2006; 4: 73-86. Available at http://www.zsf.jcu.cz/vyzkum/jab/4_2/halberg2.pdf.
106. Güllner HG, Bartter FC, Halberg F. Timing antihypertensive medication. Lancet. 1979; Sept 8: 527.
107. Levine H, Halberg F. Clinical aspects of blood pressure autorhythmometry. In: Scheving LE, Halberg F, Pauly JE, eds. Chronobiology, Proceedings of the International Society for the Study of Biological Rhythms, Little Rock, Arkansas. Tokyo: Igaku Shoin Ltd; 1974 406-414.
108. Zaslavskaya RM, Varshitsky MG, Teibloom MM. Effectiveness of chronotherapy of hypertensive patients with hypotensive drugs. In: Tarquini B, ed. Social Diseases and Chronobiology. Bologna: Esculapio; 1987: 373-380.
109. Cornélissen G, Zaslavskaya RM, Kumagai Y, Romanov Y, Halberg F. Chronopharmacologic issues in space. J Clin Pharmacol. 1994; 34: 543-551.
110. Cornélissen G, Halberg F, Prikryl P, Dankova E, Siegelova J, Dusek J. International Womb-to-Tomb Chronome Study Group. Prophylactic aspirin treatment: the merits of timing. JAMA. 1991; 266: 3128-3129.
111. Siegelova J, Cornélissen G, Dusek J, Prikryl P, Fiser B, Dankova E, Tocci A, Ferrazzani S, Hermida R, Bingham C, Hawkins D, Halberg F. Aspirin and the blood pressure and heart rate of healthy women. Policlinico (Chrono). 1995; 1(2): 43-49.
112. Hermida RC, Fernández JR, Ayala DE, Iglesias M, Halberg F. Time-dependent effects of ASA administration on blood pressure in healthy subjects. Chronobiologia. 1994; 21: 201-213.
113. Moore JG, Goo RH. Day and night aspirin-induced gastric mucosal damage and protection by ranitidine in man. Chronobiology Int. 1987; 4: 111-116.
114. Nold G, Drossard W, Lehmann K, Lemmer B. Daily variation of acute gastric mucosal injury after high- and low-dose acetylsalicylic acid. Biol Rhythm Res. 1995; 26: 428.
115. Nold G, Drossard W, Lehmann K, Lemmer B. Gastric mucosal lesions after morning versus evening application of 75 mg or 1000 mg acetylsalicylic acid (ASA). Naunyn-Schmiedeberg's Arch Pharmacol. 1995; 351: R17.
116. Prikryl P, Cornélissen G, Neubauer J, Prikryl P Jr, Karpisek Z, Watanabe Y, Otsuka K, Halberg F. Chronobiologically explored effects of telmisartan. Clin Exp Hypertens. 2005; 2 & 3: 119-128.
117. Cornélissen G, Halberg F, Schwartzkopff O, Gvozdjakova A, Siegelova J, Fiser B, Dusek J, Mifkova L, Chopra RK, Singh RB. Coenzyme-Q10 effect on blood pressure variability assessed with a chronobiological study design. In: Noninvasive Methods in Cardiology, Brno, Czech Republic, September 14, 2005. Brno: Masaryk University; 2005: 10.
118. Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Page V, Ghadirian P, LeLorier J, Hamet P. Shangai trial of nifedipine in the elderly (STONE). J Hypertens. 1996; 14: 1237-1245.
119. Liu L, Wang JG, Gong L, Liu G, Staessen JA, for the Systolic Hypertension in China (Sys-China) Collaborative Group. Comparison of active treatment and placebo for older Chinese patients with isolated systolic hypertension. J Hypertens. 1998; 16: 823-1829.
120. Shinagawa M, Kubo Y, Otsuka K, Ohkawa S, Cornélissen G, Halberg F. Impact of circadian amplitude and chronotherapy: relevance to prevention and treatment of stroke. Biomed Pharmacother. 2001; 55(suppl 1): 125-132.
121. Watanabe Y, Cornélissen G, Watanabe M, Watanabe F, Otsuka K, Ohkawa S- I, Kikuchi T, Halberg F. Effects of autogenic training and antihypertensive agents on circadian and circaseptan variation of blood pressure. Clin Exp Hypertens. 2003; 25: 405-412.
122. Tamura K, Kohno I, Saito Yuzo, Wakasugi K, Achiwa S, Imanishi Y, Cugini P, Halberg F. Antihypertensive individualized therapeutic strategy. Difesa Sociale. 1991; 6: 109-124.
123. Watanabe Y, Cornélissen G, Halberg F, Saito Y, Fukuda K, Otsuka K, Kikuchi T. Chronobiometric assessment of autogenic training effects upon blood pressure and heart rate. Perceptual Motor Skills. 1996; 83: 1395-1410.
124. Watanabe Y, Cornélissen G, Halberg F, Saito Y, Fukuda K, Revilla M, Rodriguez C, Hawkins D, Otsuka K, Kikuchi T. Method and need for continued assessment of autogenic training effect upon blood pressure: case report. New Trends Exp Clin Psychiatry. 1996; 12: 45-50.
125. Overvad K, Diamant B, Holm L, Holmer G, Mortensen SA, Stender S. Coenzyme Q10 in health and disease. Eur J Clin Nutr. 1999; 53: 764-770.
126. Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. Biofactors. 1999; 9: 273-284.
127. Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens. 2007; 21: 297-306.
128. Fok BSP, Cornélissen G, Halberg F, Chu TTW, Thomas GN, Tomlinson B. Different effects of lercanidipine and felodipine on circadian blood pressure and heart rate among hypertensive patients. Abstract 15, HK College of Cardiology, 12th Annual Science Congress. J Hong Kong Coll Cardiol. 2004; 12: 33.
129. Cornélissen G, Halberg F, Schwartzkopff O, Delmore P, Katinas G, Hunter D, Tarquini B, Tarquini R, Perfetto F, Watanabe Y, Otsuka K. Chronomes, time structures, for chronobioengineering for ''a full life''. Biomed Instrum Technol. 1999; 33: 152-187.
130. Kumagai Y, Shiga T, Sunaga K, Cornélissen G, Ebihara A, Halberg F. Usefulness of circadian amplitude of blood pressure in predicting hypertensive cardiac involvement. Chronobiologia. 1992; 19: 43-58.
131. Watanabe Y, Cornélissen G, Halberg F, Bingham C, Siegelova J, Otsuka K, Kikuchi T. Incidence pattern and treatment of a clinical entity, overswinging or circadian hyperamplitudetension (CHAT). Scr Medica. 1997; 70: 245-261.
132. Fossel M. Editorial. J Anti-Aging Med. 1998; 1: 239.
133. Picard FJ, Bergeron MG. Rapid molecular theranostics in infectious diseases. Drug Discov Today. 2002; 7: 1092-1101.
134. Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, Provost JP, Le Net JL, Baker D, Walley RJ, Everett JR, Nicholson JK. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature. 2006; 440: 1073-1077.
135. Shastry BS. Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J. 2006; 6: 16-21.
136. Mukhtar M. Evolution of biomarkers: drug discovery to personalized medicine. Drug Discov Today. 2005; 10: 1216-1218.
137. Kent D, Hayward R. When averages hide individual differences in clinical trials. Am Scientist. 2007; 95: 60-68.
138. Halberg F. Some correlations between chemical structure and maximal eosinopenia in adrenalectomized and hypophysectomized mice. J Pharmacol Exp Ther. 1952; 106: 135-149.
139. Bakken EE. One Man's Full Life. Minneapolis, MN: Medtronic Inc; 1999.
140. Bakken EE, Heruth K. Temporal control of drugs. Ann NY Acad Sci. 1991; 618: 484-489.
141. Halberg F, Cornélissen G, Otsuka K, Katinas G, Schwartzkopff O. Essays on chronomics spawned by transdisciplinary chronobiology: witness in time: Earl Elmer Bakken. Neuroendocrinol Lett. 2001; 22: 359-384.